Widespread decrease of type 1 cannabinoid receptor availability in Huntington disease in vivo

Journal of Nuclear Medicine

Volumn 51, Issue 9, 2010, Pages 1413-1417

  Van Laere, Koen ^a   Casteels, Cindy ^a   Dhollander, Isabel ^a   Goffin, Karolien ^a   Grachev, Igor ^b   Bormans, Guy ^c   Vandenberghe, Wim ^a  

^a UNIVERSITY HOSPITALS LEUVEN   (Belgium)

^b MERCK RESEARCH LABORATORIES   (United States)

^c UNIVERSITY OF LEUVEN   (Belgium)

Author keywords

Cannabinoid type 1 receptor; Huntington disease; MK 9470; PET

Indexed keywords

CANNABINOID 1 RECEPTOR; N [2 (3 CYANO PHENYL) 3 (4 (2 18 F FLUORETHOXY)PHENYL) 1 METHYLPROPYL] 2 (5 METHYL 2 PYRIDYLOXY) 2 METHYLPROPONAMIDE; RADIOLIGAND; UNCLASSIFIED DRUG;

ADOLESCENT; ADULT; ARTICLE; BRAIN STEM; CAG REPEAT; CEREBELLUM; CLINICAL ARTICLE; CONTROLLED STUDY; CORRELATION ANALYSIS; FEMALE; GENE; GENETIC TRANSCRIPTION; GRAY MATTER; HUMAN; HUNTINGTON CHOREA; IN VIVO STUDY; MALE; PREFRONTAL CORTEX; PREMOTOR CORTEX; PRIORITY JOURNAL; PROTEIN ANALYSIS; AGED; BRAIN; CASE CONTROL STUDY; METABOLISM; MIDDLE AGED; NUCLEAR MAGNETIC RESONANCE IMAGING; POSITRON EMISSION TOMOGRAPHY; SCINTISCANNING;

ADOLESCENT; ADULT; AGED; BRAIN; CASE-CONTROL STUDIES; FEMALE; HUMANS; HUNTINGTON DISEASE; MAGNETIC RESONANCE IMAGING; MALE; MIDDLE AGED; POSITRON-EMISSION TOMOGRAPHY; RECEPTOR, CANNABINOID, CB1; YOUNG ADULT;

EID: 77957051505     PISSN: 01615505     EISSN: None     Source Type: Journal    
DOI: 10.2967/jnumed.110.077156     Document Type: Article

References (25)

1. Katona I, Freund TF. Endocannabinoid signaling as a synaptic circuit breaker in neurological disease. Nat Med. 2008;14:923-930.
2. Kreitzer AC, Malenka RC. Endocannabinoid-mediated rescue of striatal LTD and motor deficits in Parkinson's disease models. Nature. 2007;445:643-647.
3. Maldonado R, Valverde O, Berrendero F. Involvement of the endocannabinoid system in drug addiction. Trends Neurosci. 2006;29:225-232.
4. Walker FO. Huntington's disease. Lancet. 2007;369:218-228.
5. Vonsattel JP, DiFiglia M. Huntington disease. J Neuropathol Exp Neurol. 1998;57:369-384.
6. Kassubek J, Juengling FD, Kioschies T, et al. Topography of cerebral atrophy in early Huntington's disease: a voxel based morphometric MRI study. J Neurol Neurosurg Psychiatry. 2004;75:213-220. (Pubitemid 38183526)
7. Dunah AW, Jeong H, Griffin A, et al. Sp1 and TAFII130 transcriptional activity disrupted in early Huntington's disease. Science. 2002;296:2238-2243. (Pubitemid 34680312)
8. Butler R, Bates GP. Histone deacetylase inhibitors as therapeutics for polyglutamine disorders. Nat Rev Neurosci. 2006;7:784-796.
9. Kuhn A, Goldstein DR, Hodges A, et al. Mutant huntingtin's effects on striatal gene expression in mice recapitulate changes observed in human Huntington's disease brain and do not differ with mutant huntingtin length or wild-type huntingtin dosage. Hum Mol Genet. 2007;16:1845-1861.
10. Glass M, Dragunow M, Faull RL. The pattern of neurodegeneration in Huntington's disease: a comparative study of cannabinoid, dopamine, adenosine and GABAA receptor alterations in the human basal ganglia in Huntington's disease. Neuroscience. 2000;97:505-519.
11. 18F]MK- 9470, a positron emission tomography (PET) tracer for in vivo human PET brain imaging of the cannabinoid-1 receptor. Proc Natl Acad Sci USA. 2007;104:9800-9805.
12. Huntington Study Group. Unified Huntington's Disease Rating Scale: reliability and consistency. Mov Disord. 1996;11:136-142. (Pubitemid 26082779)
13. 18F]MK-9470 PET. Neuroimage. 2008;39:1533-1541.
14. Penney JB Jr, Vonsattel JP, MacDonald ME, Gusella JF, Myers RH. CAG repeat number governs the development rate of pathology in Huntington's disease. Ann Neurol. 1997;41:689-692.
15. Rosas HD, Koroshetz WJ, Chen YI, et al. Evidence for more widespread cerebral pathology in early HD: an MRI-based morphometric analysis. Neurology. 2003;60:1615-1620.
16. Hayden MR, Martin WR, Stoessl AJ, et al. Positron emission tomography in the early diagnosis of Huntington's disease. Neurology. 1986;36:888-894.
17. Martin WR, Clark C, Ammann W, Stoessl AJ, Shtybel W, Hayden MR. Cortical glucose metabolism in Huntington's disease. Neurology. 1992;42:223-229.
18. Kuwert T, Lange HW, Langen KJ, Herzog H, Aulich A, Feinendegen LE. Cortical and subcortical glucose consumption measured by PET in patients with Huntington's disease. Brain. 1990;113:1405-1423.
19. Pavese N, Andrews TC, Brooks DJ, et al. Progressive striatal and cortical dopamine receptor dysfunction in Huntington's disease: a PET study. Brain. 2003;126:1127-1135.
20. Antonini A, Leenders KL, Spiegel R, et al. Striatal glucose metabolism and dopamine D2 receptor binding in asymptomatic gene carriers and patients with Huntington's disease. Brain. 1996;119:2085-2095.
21. Holthoff VA, Koeppe RA, Frey KA, et al. Positron emission tomography measures of benzodiazepine receptors in Huntington's disease. Ann Neurol. 1993;34:76-81. (Pubitemid 23188730)
22. Weeks RA, Cunningham VJ, Piccini P, Waters S, Harding AE, Brooks DJ. 11C-diprenorphine binding in Huntington's disease: a comparison of region of interest analysis with statistical parametric mapping. J Cereb Blood Flow Metab. 1997;17:943-949. (Pubitemid 27396582)
23. Curtis A, Mitchell I, Patel S, Ives N, Rickards H. A pilot study using nabilone for symptomatic treatment in Huntington's disease. Mov Disord. 2009;24:2254-2259.
24. Marsicano G, Goodenough S, Monory K, et al. CB1 cannabinoid receptors and on-demand defense against excitotoxicity. Science. 2003;302:84-88.
25. Glass M, van Dellen A, Blakemore C, Hannan AJ, Faull RL. Delayed onset of Huntington's disease in mice in an enriched environment correlates with delayed loss of cannabinoid CB1 receptors. Neuroscience. 2004;123:207-212.